Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O75444
UPID:
MAF_HUMAN
Alternative names:
Proto-oncogene c-Maf; V-maf musculoaponeurotic fibrosarcoma oncogene homolog
Alternative UPACC:
O75444; Q66I47; Q9UP93
Background:
Transcription factor Maf, also known as Proto-oncogene c-Maf, plays a pivotal role in lens fiber cell development and cellular differentiation. It regulates the expression of crystallin genes, essential for eye lens transparency and function. Additionally, it influences T-cell susceptibility to apoptosis and chondrocyte differentiation, showcasing its versatile regulatory capabilities across different tissues.
Therapeutic significance:
Given its involvement in Cataract 21 and Ayme-Gripp syndrome, both characterized by congenital cataracts and other systemic anomalies, understanding the role of Transcription factor Maf could open doors to potential therapeutic strategies. Its regulatory function in gene expression makes it a promising target for gene therapy aimed at treating or managing these complex conditions.